Engineered immune cells take on deadly brain tumors in early trial
NCT ID NCT05241392
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This early-stage study tests a new treatment called B7-H3 CAR-T cell therapy for people whose glioblastoma (a severe brain cancer) has come back. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to check safety, find the best dose, and see if it helps shrink tumors or extend survival. About 30 adults aged 18-75 are taking part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital
Beijing, Beijing Municipality, 100730, China
Conditions
Explore the condition pages connected to this study.